# A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

> **NCT02082210** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 97 (actual)

## Conditions studied

- Advanced Cancer
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Hepatocellular Cancer
- Renal Cell Carcinoma
- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Emibetuzumab
- **DRUG:** Ramucirumab

## Key facts

- **NCT ID:** NCT02082210
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-07
- **Primary completion:** 2017-12-05
- **Final completion:** 2018-01-24
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02082210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02082210, "A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02082210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*